WO1995009864A1 - Nouveau derive peptidique - Google Patents
Nouveau derive peptidique Download PDFInfo
- Publication number
- WO1995009864A1 WO1995009864A1 PCT/JP1994/001560 JP9401560W WO9509864A1 WO 1995009864 A1 WO1995009864 A1 WO 1995009864A1 JP 9401560 W JP9401560 W JP 9401560W WO 9509864 A1 WO9509864 A1 WO 9509864A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- lower alkyl
- substituted
- halogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Definitions
- the present invention relates to a novel peptide derivative having an antitumor action
- a and B represent one of the following (a) or (b):
- A represents a hydrogen atom
- B represents a phenyl group or a heteroaryl group substituted with a halogen atom, a hydroxy group, a lower alkyl group or a lower alkoxy group
- A represents one CONH—R—CSNH—R 1 , a hydroxymethyl group, a lower alkoxycarbonyl group or a carboxy group, wherein R 1 represents a lower alkyl group or a heteroaryl group, and B represents a halogen atom Represents a phenyl group which may be substituted by a hydroquine group, a lower alkyl group or a lower alkoxy group;
- the inventors of the present invention have proposed a drug that forms a drug at the C-terminus of dolastatin 10 [ ⁇ -
- Dolastatin 10 derivative is much more potent than dolastatin 10
- the term “lower” refers to a group or compound to which this term is attached.
- ⁇ means that the number of carbon atoms is 6 or less, preferably 4 or less.
- the “lower alkyl group” includes, for example, methyl, Ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-hexyl, etc.
- Examples of the “lower alkoxy” include methoxy, ethoxy, n-propoxy, Isopropoxy, n-butoxy and the like.
- the “halogen atom” includes fluorine, chlorine, bromine and iodine atoms.
- Heteroaryl group means an aromatic heterocyclic group containing a heteroatom selected from O, S and N, preferably a 5- to 6-membered heterocyclic group containing 1 to 4 heteroatoms. Examples thereof include phenyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, and triazinyl groups.
- halogen atom, hydroxy group, lower alkyl group or lower alkoxy group-substituted phenyl group represented by the symbol B includes one halogen atom, hydroxy group, lower alkyl group or lower alkoxy group.
- Substituted phenyl groups are included, for example, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3-fluorophenyl, 3-hydroxyphenyl, 4-chlorophenyl, 4-bromophenyl, 2-hydrophenyl. Examples include xyphenyl, 4-hydroxyphenyl, 2-methylphenyl, 4-ethylphenyl, 2-methoxyphenyl, and 4-ethoxyphenyl.
- the “phenyl group optionally substituted with a halogen atom, a hydroquinine group, a lower alkyl group or a lower alkoxy group” includes an unsubstituted phenyl group in addition to the above-mentioned substituted phenyl groups.
- a preferred group of compounds in the present invention is the above-mentioned compound wherein A represents a hydrogen atom and B represents a phenyl group or a heteroaryl group substituted by a halogen atom, a hydroxy group, a lower alkyl group or a lower alkoxy group.
- A represents -CONH-R-CSN-RK hydroxymethyl group, lower alkoxycarbonyl group or carboxy group, wherein R 1 represents lower alkyl group or heteroaryl group;
- B represents a halogen atom, a hydroxy group, a lower alkyl group or a furyl group which may be substituted by a lower alkoxy group
- the compound of the above formula (I) especially A is —CONH—R 1 —C SNH—R represents a hydroxymethyl group, a lower alkoxycarbonyl group or a carboxy group, wherein R 1 represents a lower alkyl group, a thiazolyl group or a thiadiazolyl group, and a formula (B) wherein B represents an unsubstituted phenyl group; Compound of I), a.
- the carbon atom to which the isopropyl group, sec-butyl group, methoxy group and methyl group are bonded is an irregular carbon atom. Or, it can have an S- configuration. Although they are all included in the scope of the present invention, compounds having the same configuration as dolastatin 10 are preferred from the viewpoint of pharmacological activity.
- the peptide compound of formula (I) may also be present as a salt, and examples of such a salt include hydrochloride, hydrobromide, trifluoroacetate, p-toluenesulfonate, Acetate and the like can be mentioned.
- the peptide compound of the formula (I) can be prepared by, for example, a liquid phase synthesis method known in the field of peptide chemistry (by Lee Schroeder and Gay Lubbe).
- the amino acids or peptide fragments can be produced by condensing each amino acid according to “The peptides”, Vol. 1, pp. 76-136, published by Ademitsu Press in 1965.
- This is preferably carried out by condensing the above-mentioned fragment with the above-mentioned fragment.
- the condensation reaction is generally carried out in an inert solvent, such as chloroform, ethyl acetate, tetrahydrofuran (THF), dimethylformamide (DMF), or acetonitrile, and, if necessary, an organic base such as triethylamine.
- an inert solvent such as chloroform, ethyl acetate, tetrahydrofuran (THF), dimethylformamide (DMF), or acetonitrile
- an organic base such as triethylamine.
- DIEA diisopropylethylamine
- condensing agents such as dicyclohexylcarpoimide (DCC) diphenylphosphoryl azide (DP PA :), cyanophosphate It can be carried out by treating with getyl (DEPC), a so-called BOP reagent or the like.
- the reaction temperature is usually about 10 ° C. to room temperature, preferably about 0 ° C.
- the ratio of each of the compound of the formula (III), the organic base and the condensing agent to the compound of the formula (II) is strictly limited.
- the compound of the formula (III) is at least 1 mole, preferably about 1.0 to 1.1 mole, and the organic base is about 2 mole per mole of the compound of the formula (II). And it is advantageous to use about 1 mol of the condensing agent.
- the compound of the formula (I) when A represents a carboxy group can also be produced by hydrolyzing the compound of the formula (I) when A represents a lower alkoxycarbonyl group with an alkali. .
- the thus obtained peptide compound of the formula (I) is isolated and purified from the reaction mixture by a method known per se, for example, recrystallization, ion exchange chromatography, gel filtration, high performance liquid chromatography, etc. It is a thing.
- the above formula (III) used as a starting material in the reaction The compounds of (IV) and (IV) are novel compounds which have not been described in the conventional literature, but can be easily produced by condensing each of the constituent amino acids by a liquid phase synthesis method.
- the peptide compound of the formula (I) of the present invention has a stronger antitumor effect than dolastatin 10 and also has a large therapeutic ratio, such as acute myeloid leukemia, acute lymphocytic leukemia, chronic melanoma, and lung melanoma. It is useful for treating adenocarcinoma, neuroblastoma, small cell lung cancer, breast cancer, colon cancer, ovarian cancer, and bladder cancer.
- the antitumor effect of the compound of the formula (I) of the present invention can be measured as follows.
- mice Seven-week-old CDF1 mice were transplanted with 0.1 ⁇ l of mouse leukemia P388 cells (10 6 cellsZ mice) intraperitoneally.
- the drug was administered intraperitoneally on the first and the fifth days of transplantation, and the survival rate (ILS,%) was calculated by the following formula from the results of observing the survival and death of mice for 60 days.
- T means the days of median survival in the drug administration group
- C means the days of median survival in the control group.
- Dolastatin When the compound of the present invention is used as a medicament, it may be in a solid form (for example, tablet, hard capsule, soft capsule, granule, powder, fine granule, pill, troche, etc.) depending on the use. Tablets, etc.), semisolid forms (eg, suppositories, ointments, etc.) or liquid forms (injections, emulsions, suspensions, lotions, sprays, etc.). .
- a solid form for example, tablet, hard capsule, soft capsule, granule, powder, fine granule, pill, troche, etc.
- Tablets, etc. may be in a solid form (for example, tablet, hard capsule, soft capsule, granule, powder, fine granule, pill, troche, etc.) depending on the use. Tablets, etc.), semisolid forms (eg, suppositories, ointments, etc.) or liquid forms (injections, emulsions, suspension
- Non-toxic additives that can be used in the above-mentioned preparations include, for example, starch, gelatin, glucose, lactose, fructose, maltose, magnesium carbonate, talc, magnesium stearate, methylcellulose, carboxymethylcellulose or salts thereof. , Gum arabic, polyethylene glycol, p-hydroxybenzoic acid alkyl ester, syrup, ethanol, propylene glycol, cellulose, carbowax, glycerin, sodium chloride, sodium sulfite, sodium phosphate, citric acid, etc. .
- the agent may also contain other therapeutically useful agents.
- the content of the compound of the present invention in the medicament varies depending on the dosage form, but it is generally in a concentration of 0.1 to 50% by weight in solid and semi-solid forms, and in a liquid form. It is desirable to contain it at a concentration of 0.05 to 10% by weight.
- the dose of the compound of the present invention can be varied widely depending on the kind of human or other warm-blooded animal, the administration route, the severity of the symptoms, the diagnosis of a doctor, etc. It can be about 50mgZkg. However, as described above, it is of course possible to administer an amount smaller than the lower limit or larger than the upper limit of the above range depending on the severity of the symptoms of the patient and the diagnosis of a doctor. The above dose can be administered once or divided into several times.
- Bu 1 is a tert-butyl group
- Boc is a tert-butoxycarbonyl group
- Bz1 is a benzyl group
- Me is a methyl group
- B is a halogen atom, a hydroxy group, a lower alkyl group or a lower alkoxy group.
- X represents a phenyl group or a heteroaryl group
- A represents —CONH—R—C SNH—R 1 , a hydroxymethyl group, a lower alkoxycarbonyl group or a carboxy group, wherein R 1 represents a lower alkyl group or Represents a heteroaryl group.
- the crude product was purified by flash chromatography on silica gel using dichloromethane-methanol (20: 1) as eluent, followed by n-hexanedichloromethane-methanol (2: 7.5: 2.5) as eluent.
- the product was purified by Sephadex LH-20 chromatography to give the desired compound 4 as an amorphous solid. 117 mg (85.0%).
- reaction solution is concentrated under reduced pressure, the residue is dissolved in ethyl acetate, washed with ice-cold 2N-hydrochloric acid and saturated aqueous sodium hydrogen carbonate, dried, and the solvent is distilled off. The residue is dissolved in ethyl acetate-ether-n-hexane. Crystallize to obtain the desired compound 6-A as needles. 1. 12 g (76.7%). 123-4 ° mp.
- Reference Example 41 The target compound 6_B is obtained from B0C-D-phenylalanine in exactly the same manner as in A.
- the crude product is purified by preparative TLC using ethyl acetate-n-hexane (3: 4) as a developing solvent to obtain the desired compound 6-C as sand crystals. 128 mg (73.6%). Melting point: 158-160 °.
- Reference Example 4 Compound 6-A obtained in A-0.27 g (0.475 mimol) and 151 mg (0.5 equivalent) of Lawesson's reagent were dissolved in 5 ml of benzene, and heated under reflux for 45 minutes. I do. The reaction mixture is evaporated to dryness under reduced pressure, and the residue is purified by preparative TLC using dichloromethane-methanol (40: 1) as a developing solvent to obtain the desired thioamide (compound 6-E) as a yellow waxy solid. 0.230 g (quantitative).
- Compound 7-K was obtained from compound 7-G in exactly the same manner as in Example 25.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94927086A EP0731106B1 (en) | 1993-10-01 | 1994-09-22 | Dolastatin derivatives |
US08/619,606 US5767237A (en) | 1993-10-01 | 1994-09-22 | Peptide derivatives |
KR1019960701664A KR100332254B1 (ko) | 1993-10-01 | 1994-09-22 | 신규인펩티드유도체 |
AT94927086T ATE282630T1 (de) | 1993-10-01 | 1994-09-22 | Dolastatin-derivate |
JP51071795A JP3469580B2 (ja) | 1993-10-01 | 1994-09-22 | 新規なペプチド誘導体 |
DE69434136T DE69434136T2 (de) | 1993-10-01 | 1994-09-22 | Dolastatin-derivate |
AU76661/94A AU689131B2 (en) | 1993-10-01 | 1994-09-22 | Novel peptide derivative |
CA002173150A CA2173150C (en) | 1993-10-01 | 1994-09-22 | Novel peptide derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5/269642 | 1993-10-01 | ||
JP26964293 | 1993-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995009864A1 true WO1995009864A1 (fr) | 1995-04-13 |
Family
ID=17475197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/001560 WO1995009864A1 (fr) | 1993-10-01 | 1994-09-22 | Nouveau derive peptidique |
Country Status (11)
Country | Link |
---|---|
US (2) | US5767237A (ja) |
EP (1) | EP0731106B1 (ja) |
JP (1) | JP3469580B2 (ja) |
KR (1) | KR100332254B1 (ja) |
AT (1) | ATE282630T1 (ja) |
AU (1) | AU689131B2 (ja) |
CA (1) | CA2173150C (ja) |
DE (1) | DE69434136T2 (ja) |
ES (1) | ES2233928T3 (ja) |
SG (1) | SG44794A1 (ja) |
WO (1) | WO1995009864A1 (ja) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840699A (en) * | 1995-04-21 | 1998-11-24 | Teikoku Hormone Mfg. Co. Ltd. | Peptide derivatives |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1390393A2 (en) * | 2001-04-30 | 2004-02-25 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
JP2007514652A (ja) * | 2003-11-06 | 2007-06-07 | シアトル ジェネティックス, インコーポレイテッド | リガンドに結合体化可能なモノメチルバリン化合物 |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
WO2013072813A2 (en) | 2011-11-17 | 2013-05-23 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
US8808679B2 (en) | 2011-06-10 | 2014-08-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
JP2016519115A (ja) * | 2013-04-25 | 2016-06-30 | ピエール、ファーブル、メディカマン | ドラスタチン10およびアウリスタチンの誘導体 |
US9433687B2 (en) | 2012-11-07 | 2016-09-06 | Pfizer Inc. | Anti-Notch3 antibodies and antibody-drug conjugates |
JP2017114847A (ja) * | 2015-11-03 | 2017-06-29 | 財團法人工業技術研究院Industrial Technology Research Institute | 化合物、リンカー−薬物およびリガンド−薬物複合体 |
JP2017519740A (ja) * | 2014-05-28 | 2017-07-20 | アジェンシス,インコーポレイテッド | ドラプロイン‐ドライソロイインペプチド誘導体 |
US10494432B2 (en) | 2007-07-16 | 2019-12-03 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10544218B2 (en) | 2008-01-31 | 2020-01-28 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10792365B2 (en) | 2016-03-29 | 2020-10-06 | Toray Industries, Inc. | Peptide derivative and use thereof |
US10981987B2 (en) | 2007-07-16 | 2021-04-20 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Families Citing this family (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE282630T1 (de) * | 1993-10-01 | 2004-12-15 | Teikoku Hormone Mfg Co Ltd | Dolastatin-derivate |
GB9625895D0 (en) * | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US7608681B2 (en) * | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
RU2448117C2 (ru) * | 2003-11-06 | 2012-04-20 | Сиэтл Дженетикс, Инк. | Монометилвалиновые соединения, способные образовывать конъюгаты с лигандами |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
MX2007003907A (es) * | 2004-10-05 | 2007-05-21 | Genentech Inc | Agentes terapeuticos con toxicidad reducida. |
EP1817336B1 (en) | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
CN101102993A (zh) * | 2005-01-13 | 2008-01-09 | 霍夫曼-拉罗奇有限公司 | 有用的双取代胺类的新型一步合成 |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス, インコーポレイテッド | フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物 |
US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
CN103030696B (zh) * | 2006-05-30 | 2016-09-28 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
HUE034263T2 (en) | 2006-10-27 | 2018-02-28 | Genentech Inc | Antibodies and immunoconjugates and their applications |
EP2468776A3 (en) | 2007-02-09 | 2012-11-14 | Genentech, Inc. | Anti-Robo4 antibodies and uses therefor |
AR066476A1 (es) | 2007-05-08 | 2009-08-19 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos |
ES2450755T3 (es) * | 2007-10-19 | 2014-03-25 | Genentech, Inc. | Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco |
JP5727786B2 (ja) | 2007-10-19 | 2015-06-03 | シアトル ジェネティクス,インコーポレーテッド | Cd19結合性物質およびその使用 |
CN102083460A (zh) | 2008-01-18 | 2011-06-01 | 米迪缪尼有限公司 | 用于位点特异性偶联的半胱氨酸工程化抗体 |
US8609105B2 (en) | 2008-03-18 | 2013-12-17 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
RU2587621C2 (ru) | 2009-04-01 | 2016-06-20 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
BRPI1012560A2 (pt) | 2009-04-01 | 2016-07-26 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
US20120213705A1 (en) | 2009-06-22 | 2012-08-23 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
KR20120123299A (ko) | 2009-12-04 | 2012-11-08 | 제넨테크, 인크. | 다중특이적 항체, 항체 유사체, 조성물 및 방법 |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
JP6048973B2 (ja) | 2010-06-03 | 2016-12-27 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートのイムノpetイメージング及びこれらの使用方法 |
CA3220104A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
EP2764351B1 (en) | 2011-09-29 | 2018-11-07 | Seattle Genetics, Inc. | Intact mass determination of protein conjugated agent compounds |
CA3182462A1 (en) | 2011-10-10 | 2013-04-18 | Xencor, Inc. | A method for purifying antibodies |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
KR20150006000A (ko) | 2012-05-01 | 2015-01-15 | 제넨테크, 인크. | 항-pmel17 항체 및 면역접합체 |
US9884127B2 (en) | 2012-05-15 | 2018-02-06 | Concortis Biosystems, Corp. | Drug-conjugates, conjugation methods, and uses thereof |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
CA2892863C (en) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
EP2928503B1 (en) | 2012-12-10 | 2019-02-20 | Mersana Therapeutics, Inc. | Conjugates of auristatin compounds |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
EP2945969A1 (en) | 2013-01-15 | 2015-11-25 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
KR20150127199A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 항-b7-h4 항체 및 면역접합체 |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
KR102561553B1 (ko) | 2013-03-15 | 2023-07-31 | 젠코어 인코포레이티드 | 이형이량체 단백질 |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
MX368258B (es) | 2013-03-15 | 2019-09-25 | Zymeworks Inc | Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos. |
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
EP3046940B1 (en) | 2013-09-17 | 2019-07-03 | F.Hoffmann-La Roche Ag | Methods of using anti-lgr5 antibodies |
PT3055331T (pt) | 2013-10-11 | 2021-04-05 | Oxford Bio Therapeutics Ltd | Anticorpos conjugados contra ly75 para o tratamento de cancro |
JP6427564B2 (ja) | 2013-10-11 | 2018-11-21 | アサナ・バイオサイエンシズ,リミテッド・ライアビリティ・カンパニー | タンパク質−ポリマー−薬物共役体 |
EP3054991B1 (en) | 2013-10-11 | 2019-04-03 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
MX2021008464A (es) | 2013-10-15 | 2023-03-03 | Seattle Genetics Inc | Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco. |
CA2934030A1 (en) | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
EA201691214A1 (ru) | 2013-12-13 | 2016-12-30 | Дженентек, Инк. | Антитела к cd33 и иммуноконъюгаты |
DK3083689T3 (da) | 2013-12-17 | 2020-08-03 | Genentech Inc | Anti-CD3-antistoffer og fremgangsmåder til anvendelse |
AU2014364812B2 (en) | 2013-12-17 | 2017-05-25 | Novartis Ag | Cytotoxic peptides and conjugates thereof |
CN106459162A (zh) | 2013-12-27 | 2017-02-22 | 酵活有限公司 | Var2csa‑药物偶联物 |
KR102384740B1 (ko) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
WO2015112909A1 (en) | 2014-01-24 | 2015-07-30 | Genentech, Inc. | Methods of using anti-steap1 antibodies and immunoconjugates |
PT3122757T (pt) | 2014-02-28 | 2023-11-03 | Hangzhou Dac Biotech Co Ltd | Ligantes carregados e as suas utilizações em conjugação |
UA119167C2 (uk) | 2014-03-28 | 2019-05-10 | Зенкор, Інк. | Біспецифічне антитіло, яке зв'язується з cd38 та cd3 |
EP3607996B1 (en) | 2014-04-25 | 2023-01-04 | Pierre Fabre Medicament | Antibody-drug-conjugate and its use for the treatment of cancer |
AU2015250759B2 (en) | 2014-04-25 | 2017-11-30 | Pierre Fabre Medicament | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer |
JP6681346B2 (ja) | 2014-06-13 | 2020-04-15 | ノバルティス アーゲー | オーリスタチン誘導体およびその抱合体 |
AU2015292326A1 (en) | 2014-07-24 | 2017-02-23 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US20170260261A1 (en) | 2014-08-28 | 2017-09-14 | Bioatla, Llc | Conditionally Active Chimeric Antigen Receptors for Modified T-Cells |
JP6943760B2 (ja) | 2014-09-12 | 2021-10-06 | ジェネンテック, インコーポレイテッド | 抗b7−h4抗体及び免疫複合体 |
CA2958479A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
US9518118B2 (en) | 2014-09-12 | 2016-12-13 | Genentech, Inc. | Anti-HER2 antibodies and immunoconjugates |
CN107108724A (zh) | 2014-09-12 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 半胱氨酸改造抗体和缀合物 |
HUE057768T2 (hu) | 2014-09-17 | 2022-06-28 | Zymeworks Inc | Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei |
CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
JP6871858B2 (ja) | 2015-01-28 | 2021-05-19 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | 抗体薬物コンジュゲート |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
JP6871874B2 (ja) | 2015-06-16 | 2021-05-19 | ジェネンテック, インコーポレイテッド | FcRH5に対するヒト化親和性成熟抗体及び使用方法 |
EP3319936A4 (en) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
JP6928354B2 (ja) | 2015-07-24 | 2021-09-01 | ペティット,ジョージ,ロバート | クインスタチン化合物 |
US10722593B2 (en) * | 2015-10-02 | 2020-07-28 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
KR102626498B1 (ko) | 2016-03-25 | 2024-01-19 | 씨젠 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
LT3455261T (lt) | 2016-05-13 | 2022-11-10 | Bioatla, Inc. | Antikūnai prieš ror2, antikūnų fragmentai, jų imunokonjugatai ir panaudojimas |
JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック, インコーポレイテッド | 部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法 |
WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
EP3474901A1 (en) | 2016-06-27 | 2019-05-01 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
AU2017290086A1 (en) | 2016-06-28 | 2019-01-24 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US11066479B2 (en) | 2016-08-02 | 2021-07-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
JP7138350B2 (ja) | 2016-11-14 | 2022-09-16 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | 共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法 |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
CA3056134A1 (en) | 2017-03-24 | 2018-09-27 | Seattle Genetics, Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
WO2018192407A1 (zh) * | 2017-04-19 | 2018-10-25 | 四川科伦博泰生物医药股份有限公司 | 细胞毒素和偶联物、其用途和制备方法 |
EP3625256A1 (en) | 2017-05-19 | 2020-03-25 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Human monoclonal antibody targeting tnfr2 for cancer immunotherapy |
EP3641826B1 (en) | 2017-06-22 | 2023-12-06 | Mersana Therapeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
JP2020529832A (ja) | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質 |
WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
CA3066953A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | Human monoclonal antibodies specific for cd33 and methods of their use |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US11970506B2 (en) | 2017-12-15 | 2024-04-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive molecule conjugate, preparation method and use thereof |
WO2019125732A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
US20210308207A1 (en) | 2018-05-04 | 2021-10-07 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
WO2019212356A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B .V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
WO2020010079A2 (en) | 2018-07-02 | 2020-01-09 | Amgen Inc. | Anti-steap1 antigen-binding protein |
WO2020014482A1 (en) | 2018-07-12 | 2020-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Affinity matured cd22-specific monoclonal antibody and uses thereof |
US20210292428A1 (en) | 2018-08-08 | 2021-09-23 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
CA3115096A1 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
EA202191175A1 (ru) | 2018-10-29 | 2021-09-08 | Мерсана Терапьютикс, Инк. | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры |
MX2021006573A (es) | 2018-12-06 | 2021-07-15 | Genentech Inc | Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20. |
EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
WO2020146182A1 (en) | 2019-01-08 | 2020-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross-species single domain antibodies targeting mesothelin for treating solid tumors |
EP3883971A1 (en) | 2019-01-22 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
BR112021022815A2 (pt) | 2019-05-14 | 2021-12-28 | Genentech Inc | Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina |
US20230121556A1 (en) | 2019-06-17 | 2023-04-20 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
CN114174341A (zh) | 2019-07-08 | 2022-03-11 | 英凯尔生物科技有限责任公司 | 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法 |
CN114901699A (zh) | 2019-09-11 | 2022-08-12 | 英凯尔生物科技有限责任公司 | 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体的表位 |
CN114945386A (zh) | 2019-10-18 | 2022-08-26 | 基因泰克公司 | 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法 |
JP2022552875A (ja) | 2019-10-22 | 2022-12-20 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ |
EP4041769A1 (en) | 2019-12-12 | 2022-08-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Antibody-drug conjugates specific for cd276 and uses thereof |
EP4077391A1 (en) | 2019-12-18 | 2022-10-26 | Teneofour, Inc. | Heavy chain antibodies binding to cd38 |
BR112022021441A2 (pt) | 2020-04-24 | 2022-12-13 | Genentech Inc | Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
WO2022093745A1 (en) | 2020-10-26 | 2022-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
CA3218170A1 (en) | 2021-05-12 | 2022-11-17 | Jamie Harue HIRATA | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
EP4352099A1 (en) | 2021-06-09 | 2024-04-17 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
TW202337499A (zh) | 2021-08-07 | 2023-10-01 | 美商建南德克公司 | 使用抗cd79b免疫結合物治療瀰漫性大b細胞淋巴瘤之方法 |
CA3230774A1 (en) | 2021-09-06 | 2023-03-09 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
CA3238627A1 (en) | 2021-11-25 | 2023-06-01 | Christine Kohler | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023104941A1 (en) | 2021-12-08 | 2023-06-15 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
WO2023158305A1 (en) | 2022-02-15 | 2023-08-24 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
WO2024080872A1 (en) | 2022-10-12 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Strained bicyclononenes |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003054A1 (en) * | 1991-08-09 | 1993-02-18 | Teikoku Hormone Mfg. Co., Ltd. | Novel tetrapeptide derivative |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US4978744A (en) * | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5635483A (en) * | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5410024A (en) * | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) * | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
ATE282630T1 (de) * | 1993-10-01 | 2004-12-15 | Teikoku Hormone Mfg Co Ltd | Dolastatin-derivate |
US5840699A (en) * | 1995-04-21 | 1998-11-24 | Teikoku Hormone Mfg. Co. Ltd. | Peptide derivatives |
US5939527A (en) * | 1996-07-30 | 1999-08-17 | Basf Aktiengesellschaft | Tetrapeptides as antitumor agents |
-
1994
- 1994-09-22 AT AT94927086T patent/ATE282630T1/de not_active IP Right Cessation
- 1994-09-22 CA CA002173150A patent/CA2173150C/en not_active Expired - Fee Related
- 1994-09-22 ES ES94927086T patent/ES2233928T3/es not_active Expired - Lifetime
- 1994-09-22 JP JP51071795A patent/JP3469580B2/ja not_active Expired - Fee Related
- 1994-09-22 AU AU76661/94A patent/AU689131B2/en not_active Ceased
- 1994-09-22 EP EP94927086A patent/EP0731106B1/en not_active Expired - Lifetime
- 1994-09-22 KR KR1019960701664A patent/KR100332254B1/ko not_active IP Right Cessation
- 1994-09-22 DE DE69434136T patent/DE69434136T2/de not_active Expired - Fee Related
- 1994-09-22 US US08/619,606 patent/US5767237A/en not_active Expired - Fee Related
- 1994-09-22 WO PCT/JP1994/001560 patent/WO1995009864A1/ja active IP Right Grant
-
1996
- 1996-04-11 SG SG1996007713A patent/SG44794A1/en unknown
-
1998
- 1998-03-16 US US09/039,426 patent/US6124431A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003054A1 (en) * | 1991-08-09 | 1993-02-18 | Teikoku Hormone Mfg. Co., Ltd. | Novel tetrapeptide derivative |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840699A (en) * | 1995-04-21 | 1998-11-24 | Teikoku Hormone Mfg. Co. Ltd. | Peptide derivatives |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1390393A2 (en) * | 2001-04-30 | 2004-02-25 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1390393A4 (en) * | 2001-04-30 | 2006-05-24 | Seattle Genetics Inc | PENTAPEPTIDE COMPOUNDS AND USES THEREOF |
US7098308B2 (en) | 2001-04-30 | 2006-08-29 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US8906376B2 (en) | 2002-07-31 | 2014-12-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP2353611A2 (en) | 2002-07-31 | 2011-08-10 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7659241B2 (en) | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7829531B2 (en) | 2002-07-31 | 2010-11-09 | Seattle Genetics Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7851437B2 (en) | 2002-07-31 | 2010-12-14 | Seattle Genetics Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP2357006A2 (en) | 2002-07-31 | 2011-08-17 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US8703714B2 (en) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US10414826B2 (en) | 2003-11-06 | 2019-09-17 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
JP2011231131A (ja) * | 2003-11-06 | 2011-11-17 | Seattle Genetics Inc | リガンドに結合体化可能なモノメチルバリン化合物 |
JP2007514652A (ja) * | 2003-11-06 | 2007-06-07 | シアトル ジェネティックス, インコーポレイテッド | リガンドに結合体化可能なモノメチルバリン化合物 |
JP2013151567A (ja) * | 2003-11-06 | 2013-08-08 | Seattle Genetics Inc | リガンドに結合体化可能なモノメチルバリン化合物 |
US8557780B2 (en) | 2003-11-06 | 2013-10-15 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US10808039B2 (en) | 2003-11-06 | 2020-10-20 | Seattle Genetics Inc. | Monomethylvaline compounds capable of conjugation to ligands |
JP2011121969A (ja) * | 2003-11-06 | 2011-06-23 | Seattle Genetics Inc | リガンドに結合体化可能なモノメチルバリン化合物 |
US7745394B2 (en) | 2003-11-06 | 2010-06-29 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US10494432B2 (en) | 2007-07-16 | 2019-12-03 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
USRE48558E1 (en) | 2007-07-16 | 2021-05-18 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10981987B2 (en) | 2007-07-16 | 2021-04-20 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
US11866496B2 (en) | 2007-07-16 | 2024-01-09 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
US10544218B2 (en) | 2008-01-31 | 2020-01-28 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US8808679B2 (en) | 2011-06-10 | 2014-08-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
US9249186B2 (en) | 2011-11-17 | 2016-02-02 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
EP3327027A1 (en) | 2011-11-17 | 2018-05-30 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
US9138486B2 (en) | 2011-11-17 | 2015-09-22 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
US8828401B2 (en) | 2011-11-17 | 2014-09-09 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
WO2013072813A2 (en) | 2011-11-17 | 2013-05-23 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
US9433687B2 (en) | 2012-11-07 | 2016-09-06 | Pfizer Inc. | Anti-Notch3 antibodies and antibody-drug conjugates |
JP2016519115A (ja) * | 2013-04-25 | 2016-06-30 | ピエール、ファーブル、メディカマン | ドラスタチン10およびアウリスタチンの誘導体 |
JP2017519740A (ja) * | 2014-05-28 | 2017-07-20 | アジェンシス,インコーポレイテッド | ドラプロイン‐ドライソロイインペプチド誘導体 |
US11312748B2 (en) | 2014-05-28 | 2022-04-26 | Agensys, Inc. | Derivatives of dolaproine-dolaisoleucine peptides |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
US10683327B2 (en) | 2015-11-03 | 2020-06-16 | Industrial Technology Research Institute | Compounds, linker-drugs and ligand-drug conjugates |
US10618935B2 (en) | 2015-11-03 | 2020-04-14 | Industrial Technology Research Institute | Antibody-drug conjugate (ADC) and method for forming the same |
US10233212B2 (en) | 2015-11-03 | 2019-03-19 | Industrial Technology Research Institute | Compounds, linker-drugs and ligand-drug conjugates |
JP2017114847A (ja) * | 2015-11-03 | 2017-06-29 | 財團法人工業技術研究院Industrial Technology Research Institute | 化合物、リンカー−薬物およびリガンド−薬物複合体 |
US10792365B2 (en) | 2016-03-29 | 2020-10-06 | Toray Industries, Inc. | Peptide derivative and use thereof |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
KR100332254B1 (ko) | 2002-09-27 |
KR960704919A (ko) | 1996-10-09 |
AU689131B2 (en) | 1998-03-26 |
US5767237A (en) | 1998-06-16 |
CA2173150A1 (en) | 1995-04-13 |
DE69434136T2 (de) | 2005-12-01 |
EP0731106B1 (en) | 2004-11-17 |
AU7666194A (en) | 1995-05-01 |
EP0731106A1 (en) | 1996-09-11 |
CA2173150C (en) | 2004-11-30 |
SG44794A1 (en) | 1997-12-19 |
DE69434136D1 (de) | 2004-12-23 |
JP3469580B2 (ja) | 2003-11-25 |
ES2233928T3 (es) | 2005-06-16 |
EP0731106A4 (en) | 1998-12-23 |
US6124431A (en) | 2000-09-26 |
ATE282630T1 (de) | 2004-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995009864A1 (fr) | Nouveau derive peptidique | |
KR100408909B1 (ko) | 신규펩티드유도체 | |
JP2618597B2 (ja) | 新規なテトラペプチド誘導体 | |
US5084468A (en) | Dc-88a derivatives | |
JP2001502319A (ja) | 成長ホルモンの放出を促進するベンズオキセピン誘導体 | |
JPH02124862A (ja) | シクロアルキル置換されたグルタルアミド抗高血圧剤 | |
JPH07113027B2 (ja) | K−252誘導体 | |
US5703106A (en) | Antagonists of endothelin receptors | |
JPH06234790A (ja) | 新規テトラペプチドアミド誘導体 | |
US5587375A (en) | Azepinone compounds useful in the inhibition of ACE and NEP | |
EP1847536A1 (en) | Synthesis and uses of pyroglutamic acid derivatives | |
WO1992021696A1 (en) | Hydroxyazido derivatives and related compounds as renin inhibitors | |
JPS6238353B2 (ja) | ||
JPH01199962A (ja) | ピペリジン化合物 | |
US20030191053A1 (en) | Cyclic peptide derivative | |
JP3810129B2 (ja) | 新規なフエネチルアミド誘導体 | |
JP3782507B2 (ja) | 新規なn−メチルプロリン誘導体 | |
JP3157341B2 (ja) | テトラヒドロチオピラン誘導体 | |
JPH024767A (ja) | 薬理作用を有するペプチド類 | |
JP2828548B2 (ja) | 新規な2−ピペリジンカルボン酸誘導体 | |
JPS6110578A (ja) | 1−および/または3−置換−4−オキソ−2−アゼチジニルカルボニル誘導体およびその製造法 | |
JPH06107635A (ja) | 新規なコハク酸誘導体 | |
JPS62223193A (ja) | β−遮断およびACE抑制化合物 | |
JPH05331186A (ja) | ジペプチド、その製造方法及びエンドセリン拮抗剤 | |
JPH0565225A (ja) | 発癌遺伝子抑制剤及び復帰突然変異細胞取得剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2173150 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019960701664 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08619606 Country of ref document: US Ref document number: 1994927086 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994927086 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994927086 Country of ref document: EP |